<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="92397">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01889654</url>
  </required_header>
  <id_info>
    <org_study_id>5543</org_study_id>
    <nct_id>NCT01889654</nct_id>
  </id_info>
  <brief_title>Anti-nucleosome B Lymphocytes in Lupus</brief_title>
  <official_title>Analysis of Frequency and Phenotype of Anti-nucleosome B Lymphocyte in Systemic Lupus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lupus disease is characterized by the production of pathogenic autoantibodies, which
      participate in end-organ damages. The phenotype of B cells producing the pathogenic
      autoantibodies in lupus patients is today unknown. Antinucleosome antibodies are
      characteristic of lupus disease.This project proposes to detect antinucleosome B cells in
      lupus patients and to analyse their phenotype and their frequency.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>all cause mortality</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Systemic Lupus Erythematosus With or Without Clinical Activity</condition>
  <arm_group>
    <arm_group_label>patient</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy volunteers</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Venous blood sampling</intervention_name>
    <arm_group_label>patient</arm_group_label>
    <arm_group_label>healthy volunteers</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        lupus patient and healthy volunteers
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria for SLE patients:

        SLE patient : diagnostic based on ACR criteria

          -  SLE patient producing seric anti-nucleosome antibodies (ELISA)

          -  SLEDAI-2K activity score : inferior to 5 for quiescent patients, superior to 8 since
             at least 2 months for active patients

        Exclusion criteria for SLE patients:

        -- Other autoimmune diseases than SLE- Induced lupus

          -  Treatment with corticosteroids &gt;10mg/d (prednisone) for  quiescent patients

          -  Treatment with corticosteroids &gt;20mg/d (prednisone) for  active patients

          -  Oral immunosuppressive treatment during the last 6 months (methotrexate,
             azathioprine, ciclosporine, mycophénolate mofétil) for all patients,  treatment
             during the last year with  cyclophosphamide or monoclonal antibodies (rituximab,
             belimumab) for pour quiescent patients

          -  Disease which can modify B and T lymphocyte functions: primary immune deficiencies,
             evolutive infections, chronic viral infection (VIH in particular), chemotherapy or
             neoplasm antecedent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pauline Soulas-Sprauel, MD</last_name>
    <email>pauline.soulas@ibmc-cnrs.unistra.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Les Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <state>Bas Rhin</state>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pauline Soulas Sprauel, M</last_name>
    </contact>
    <investigator>
      <last_name>Anne-Sophie KORGANOW, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catherine MUTTER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pauline Soulas Sprauel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 14, 2014</lastchanged_date>
  <firstreceived_date>June 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
